Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 7.92 as of 2026-10-06T13:35:29.810Z.
Consensus retrieved: 2026-10-06T08:50:08.503Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T13:35:29.810Z.
Quote observation: 2026-10-06T13:34:30.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: beedc7da254cde129027c6fa8bccd4f2d15084140463b87e0d2a50d7b49590bc
Forward PE Ratio (7.92) = Dated Quote Price ($73.41) / Consensus Forward EPS ($9.27)
FORWARD PE RATIO
7.92
SECTOR MEDIAN · HEALTHCARE
19.26
median of 146 covered companies
CURRENT VS SECTOR MEDIAN
-58.88%
vs the sector median at left
ANI Pharmaceuticals, Inc.
Market Cap
$1.67B
Forward PE Ratio
7.92
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| ANI Pharmaceuticals, Inc. (ANIP) | $1.67B | 7.92 |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.67B | 33.15 |
| Kestra Medical Technologies, Ltd. (KMTS)vs › | $1.69B | N/A |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.71B | 5.61 |
| Alignment Healthcare, Inc. (ALHC)vs › | $1.72B | 45.77 |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.74B | N/A |
| Certara, Inc. (CERT)vs › | $1.58B | 29.86 |
| Generate Biomedicines, Inc. (GENB)vs › | $1.77B | N/A |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.53B | 51.35 |
| Innoviva, Inc. (INVA)vs › | $1.53B | 8.54 |
Trailing P/E
15.9
reported TTM EPS
Forward P/E
7.9
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $9.27 implies +100.2% EPS growth vs the reported trailing $4.63.
At the dated quote price of $73.41, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $9.27 | $9.20 – $9.37 | 5 | 7.9x |
| 2027-12-31 | $10.40 | $9.94 – $11.24 | 5 | 7.1x |
| 2028-12-31 | $11.97 | $11.89 – $12.06 | 2 | 6.1x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
